L
Linda Davidson-Ray
Researcher at Duke University
Publications - 42
Citations - 7492
Linda Davidson-Ray is an academic researcher from Duke University. The author has contributed to research in topics: Myocardial infarction & Acute coronary syndrome. The author has an hindex of 18, co-authored 35 publications receiving 6996 citations. Previous affiliations of Linda Davidson-Ray include University of Louisville & Riverside Methodist Hospital.
Papers
More filters
Journal ArticleDOI
Amiodarone or an implantable cardioverter-defibrillator for congestive Heart failure
Gust H. Bardy,Kerry L. Lee,Daniel B. Mark,Jeanne E. Poole,Douglas L. Packer,Robin Boineau,Michael J. Domanski,Charles Troutman,Jill Anderson,Steven McNulty,Nancy E. Clapp-Channing,Linda Davidson-Ray,Elizabeth S. Fraulo,Daniel P. Fishbein,Richard M. Luceri,John Ip +15 more
TL;DR: In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.
Journal ArticleDOI
Cost-Effectiveness of Defibrillator Therapy or Amiodarone in Chronic Stable Heart Failure Results From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
Daniel B. Mark,Charlotte L. Nelson,Kevin J. Anstrom,Sana M. Al-Khatib,Anastasios A. Tsiatis,Patricia A. Cowper,Nancy E. Clapp-Channing,Linda Davidson-Ray,Jeanne E. Poole,George Johnson,Jill Anderson,Kerry L. Lee,Gust H. Bardy +12 more
TL;DR: Prophylactic use of single-lead, shock-only I CD therapy is economically attractive in patients with stable, moderately symptomatic heart failure with an ejection fraction ≤35%, particularly those in NYHA class II, as long as the benefits of ICD therapy observed in the SCD-HeFT persist for at least 8 years.
Journal ArticleDOI
Quality of life with defibrillator therapy or amiodarone in heart failure.
Daniel B. Mark,Kevin J. Anstrom,Jie L. Sun,Nancy E. Clapp-Channing,Anastasios A. Tsiatis,Linda Davidson-Ray,Kerry L. Lee,Gust H. Bardy +7 more
TL;DR: In a large primary-prevention population with moderately symptomatic heart failure, single-lead ICD therapy was not associated with any detectable adverse quality-of-life effects during 30 months of follow-up.
Journal ArticleDOI
Economic Assessment of Low-Molecular-Weight Heparin (Enoxaparin) Versus Unfractionated Heparin in Acute Coronary Syndrome Patients Results From the ESSENCE Randomized Trial
Daniel B. Mark,Patricia A. Cowper,Scott D. Berkowitz,Linda Davidson-Ray,Elizabeth R. DeLong,Alexander G.G. Turpie,Robert M. Califf,Beth D. Weatherley,Marc Cohen +8 more
TL;DR: In patients with acute coronary syndrome, low-molecular-weight heparin (enoxaparin) both improves important clinical outcomes and saves money relative to therapy with standard unfractionated heparins.
Journal ArticleDOI
Economic Assessment of Platelet Glycoprotein IIb/IIIa Inhibition for Prevention of Ischemic Complications of High-Risk Coronary Angioplasty
Daniel B. Mark,J. David Talley,Eric J. Topol,Lee Bowman,Lai Choi Lam,Keaven M. Anderson,James G. Jollis,Michael W. Cleman,Kerry L. Lee,Thomas Aversano,William J. Untereker,Linda Davidson-Ray,Robert M. Califf +12 more
TL;DR: In high-risk coronary angioplasty, aggressive platelet inhibition with c7E3 Fab, by significantly reducing ischemic events and repeat revascularization, recoups most of the cost of therapy and has the potential to pay for itself.